We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AVIR market cap is 267.75M. The company's latest EPS is USD -1.6097 and P/E is -1.97.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -41.57M | -35.24M | -40.79M | -46.57M | -69.81M |
| Net Income | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 48.63M | 351.37M | 0 | 0 |
| Operating Income | -14.61M | -11.03M | 138.38M | -130.65M | -164.16M |
| Net Income | -14.03M | -10.95M | 121.19M | -116.59M | -135.96M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 638.13M | 626.03M | 608.08M | 594.97M | 553.03M |
| Total Liabilities | 19.95M | 23.68M | 26.35M | 39.78M | 48.66M |
| Total Equity | 618.18M | 602.35M | 581.73M | 555.19M | 504.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 22.07M | 863.63M | 772.89M | 666.71M | 594.97M |
| Total Liabilities | 2.53M | 315.83M | 62.82M | 26.14M | 39.78M |
| Total Equity | -49.57M | 547.8M | 710.08M | 640.57M | 555.19M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.85M | -45.97M | -63.56M | -85.4M | -39.87M |
| Investing | 24.48M | 71.05M | 12.53M | 40.3M | 56.8M |
| Financing | 165k | 165k | 257k | 257k | 150k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.81M | 296.73M | -87.01M | -120.98M | -85.4M |
| Investing | -2k | -26k | -4k | -455.41M | 40.3M |
| Financing | -15k | 531.75M | 1.47M | 370k | 257k |
| Market Cap | 267.75M |
| Price to Earnings Ratio | -1.97 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.86 |
| Price to Book Ratio | 0.48 |
| Dividend Yield | - |
| Shares Outstanding | 84.46M |
| Average Volume (1 week) | 223.06k |
| Average Volume (1 Month) | 171.64k |
| 52 Week Change | 4.62% |
| 52 Week High | 4.60 |
| 52 Week Low | 2.30 |
| Spread (Intraday) | 1.28 (30.48%) |
| Company Name | Atea Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.ateapharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
